The most widely used classification to risk-stratify prostate cancer patients is the D’Amico classification, which divides patients into low-, intermediate-, and high-risk groups[17] and takes into consideration PSA level, Gleason score, and clinical tumor stage. This evidence concerns the gene KLK3 and Familial prostate cancer.